We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Randox Laboratories

  Platinum Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biochemical Parameters Compared for Diabetic Ketoacidosis Severity

By LabMedica International staff writers
Posted on 19 Jan 2022
Print article
Image: The D-3-Hydroxybutyrate (Ranbut) assay is a superior marker of ketoacidosis (Photo courtesy of Randox)
Image: The D-3-Hydroxybutyrate (Ranbut) assay is a superior marker of ketoacidosis (Photo courtesy of Randox)
Diabetic ketoacidosis (DKA) is a life-threatening acute complication of diabetes mellitus characterized by hyperglycemia and ketoacidosis. It can occur in both type 1 diabetes (T1DM) and type 2 (T2DM) diabetes patients under stress conditions.

Laboratory findings in DKA consist of hyperglycemia, high anion gap metabolic acidosis, and detection of serum ketone or urine ketone bodies. Three types of ketone bodies, acetoacetate, beta-hydroxybutyrate (BHB), and acetone, are produced in DKA. The ratio of BHB to acetoacetate in patients with DKA is increased by 10 times compared with the healthy population.

Endocrinologists at the Maharaj Nakorn Si Thammarat Hospital (Muang, Thailand) and their colleagues recruited 99 patients with type 1 or type 2 diabetes mellitus that were diagnosed with DKA between October 1, 2018 and September 30, 2020 into a prospective observational study. The inclusion criteria were: age > 18 years, diagnosed with DKA and admitted to the hospital, serum blood glucose ≥250 mg/dL and serum BHB ≥3 mmol/L, and venous blood pH < 7.3 or serum bicarbonate < 18 mmol/L.

Serum BHB was measured by an enzymatic method, the Ranbut assay, (Randox Laboratories Limited, Crumlin, UK). The test was linear for serum BHB at 0.1–5.75 mmol/L and had a correlation coefficient of r = 0.9954. Serum glucose, blood urea nitrogen (BUN), creatinine, serum lactate, and serum electrolytes were measured using a c501 module of the Cobas 6000 analyzer series (Roche Diagnostics, Rotkreuz, Switzerland).

The investigators reported a total of 99 diabetes patients were diagnosed with DKA (mean age 39.4 years, 63.4% female, 53.6% T2DM). while infection was the most common precipitating factor in T2DM (43.4%), non-compliance with treatment was the most common precipitating factor in T1DM (43.5%). The initial laboratories evaluation of patients did not significant differ between type1 and type2 diabetes. Serum BHB during treatment of DKA was significantly correlated with changes in serum bicarbonate, serum anion gap, and venous pH. The serum BHB levels corresponding to HCO3 levels for DKA severity were 4.5, 5.7, and 5.9 mmol/L in mild, moderate, and severe DKA, respectively. The serum BHB level of < 1 mmol/L had 73.7% sensitivity and 100% specificity to predict DKA resolution. Median time to resolution of DKA was 12 hours with an optimized BHB cut-off value of < 1 mmol/L. There were no significant difference in time to resolution of DKA in the patients with type 1 and type 2 diabetes.

The authors concluded there are no differences in DKA-related biochemical parameters between type 1 and type 2 diabetes patients. The present findings suggest that DKA should be assessed and treated similarly, regardless of its occurrence in type 1 or type 2 diabetes patients. The study was published on January 6, 2022 in the journal BMC Endocrine Disorders.

Related Links:
Maharaj Nakorn Si Thammarat Hospital
Randox Laboratories
Roche Diagnostics

Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
Urine Analyzer
Chemiluminescence Analyzer
DZ-Lite 3000 Plus

Print article


Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.